Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)

Neurology·MeSH: Inclusion Body Myopathy With Early-Onset Paget Disease And Frontotemporal Dementia

Prevalence

0.1 / 100K

0 drugs in development·0 companies·1 clinical trial

Frequently asked questions

How many clinical trials target Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)?

There are 1 clinical trial targeting Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD) tracked by BioSniper.

What is the prevalence of Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)?

The estimated prevalence of Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD) is approximately 0.1 per 100,000 population.

Deep-dive into Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD) — Drugs in Development & Clinical Trials | BioSniper